Targeting human langerin promotes HIV-1 specific humoral immune responses.

Targeting human langerin promotes HIV-1 specific humoral immune responses.

The main avenue for the development of an HIV-1 vaccine remains the induction of protective antibodies. A rationale approach is to target antigen to specific receptors on dendritic cells (DC) via fused monoclonal antibodies (mAb). In mouse and non-human primate models, targeting of skin Langerhans c...

Full description

Bibliographic Details
Main Authors: Jérôme Kervevan, Aurélie Bouteau, Juliane S Lanza, Adele Hammoudi, Sandra Zurawski, Mathieu Surenaud, Lydie Dieudonné, Marion Bonnet, Cécile Lefebvre, Hakim Hocini, Romain Marlin, Aurélie Guguin, Barbara Hersant, Oana Hermeziu, Elisabeth Menu, Christine Lacabaratz, Jean-Daniel Lelièvre, Gerard Zurawski, Véronique Godot, Sandrine Henri, Botond Z Igyártó, Yves Levy, Sylvain Cardinaud
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-07-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1009749

Internet

https://doi.org/10.1371/journal.ppat.1009749

Similar Items